Johnson and Johnson, Pharma tariffs can cause drug failure

Be informed with free updates

Simply register Pharmaceutical sector Myft Digest – Delivered directly to your box.

Johnson and Johnson’s CEO of Johnson warned that potential US tariffs in the drug industry could lead to drug failure.

This month was removed from the extensive tariffs announced, but the Trump management clarified that he was used to try to increase internal production.

The US currently has no tariffs for the 1994 World Trade Organization in the trade deal.

Joaquin Duato, leading to one of the world’s largest pharma and medical device companies, said that he was in a call with Tuesday analysts

Medical device and technology like surgical robots made by J & J hit new US tariffs.

“What you want, both in Med Tech, but also in medicines, but also an effective response and tax policy,” he said.

In March, J & J, in the next four years in the United States will invest $ 55 billion in new plants, and compared to the previous four years, the investment increases increased by 25 percent.

Monday, The US leadership said This was investigated by the national security effects of relying on drug imports. Probe began on April 1 and consult within 21 days.

Duato, along with the management of healthcare companies, thinking it is important to work with “reducing some of the existing vulnerabilities”, in response to a question about investigative and potential tariffs.

J & J’s Chief Financial Officer Joe Wolk said the company said they wanted to “postpone for management and their process.”

The pharmaceutical industry is generally prevented from condemning the tariffs, and hopes to overcome the talks behind the scenes. However, Duato’s statements, after arrival after Michel Demaré, Astrazeneca department, the tariffs could damage patients, health systems and warned “restricting health care”.

The results published on Tuesday, J & J, despite factoring for about $ 400 million in medical devices, maintained the diluted profit of 10.50 – 10.70.

In the first quarter of the year, its sales were $ 21.9 billion, 2.4 percent from the same period last year. Analysts waited for $ 21.6 billion.